Literature DB >> 8058318

A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression.

M Kitagawa1, H Higashi, I S Takahashi, T Okabe, H Ogino, Y Taya, S Hishimura, A Okuyama.   

Abstract

Butyrolactone I is a selective inhibitor of the cyclin-dependent kinase (cdk) family. It inhibits both cdk2 and cdc2 kinase, but scarcely affects C-kinase, A-kinase, casein kinases, MAP kinase or EGF receptor-tyrosine kinase (Kitagawa et al., 1993, Oncogene, 8, 2425-2432). We studied the effects of butyrolactone I on the cell cycle as well as on phosphorylation of retinoblastoma protein (pRB). Butyrolactone I inhibited phosphorylation of pRB catalyzed by cyclin A-cdk2 produced by baculovirus in vitro. Furthermore, it inhibited phosphorylation of pRB and cell cycle progression from G1 to S phase in WI38 cell cultures. WI38 cells arrested at the G0 phase by serum starvation progressed in the cell cycle after serum stimulation. pRB was phosphorylated after 10 h serum stimulation. Incorporation of [3H]thymidine into the cells began to increase after 16 h serum stimulation. These processes were inhibited by butyrolactone I. Flow cytometric analysis showed that exposure to butyrolactone I inhibited progression of the cell cycle from G1 to S phase. These data suggested that initiation of DNA synthesis was inhibited by butyrolactone I and that the cell cycle was arrested in the G1 phase. Butyrolactone I also inhibited H1 histone phosphorylation in human WI38 cells and their G2/M progression. tsFT210 cells, a temperature-sensitive cdc2 mutant cell line, were synchronized at G2/M at a nonpermissive temperature, butyrolactone I inhibited the cell cycle progression of these cells at G2/M at the permissive temperature. Thus butyrolactone I, a cyclin-dependent kinase family inhibitor, which prevented the phosphorylations of the cell cycle-regulating proteins pRB and H1 histone, inhibited the cell cycle at G1/S and G2/M, respectively. These results suggest that the phosphorylations of pRB and H1 histone may play crucial roles in G1/S and G2/M progression, respectively, although it is possible that phosphorylations of other proteins by cdks are involved in G1/S and G2/M progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058318

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

Review 2.  Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses.

Authors:  H M Davey; D B Kell
Journal:  Microbiol Rev       Date:  1996-12

3.  Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells.

Authors:  K Fukuoka; J Usuda; Y Iwamoto; H Fukumoto; T Nakamura; T Yoneda; N Narita; N Saijo; K Nishio
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

4.  The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2.

Authors:  M Kitagawa; H Higashi; H K Jung; I Suzuki-Takahashi; M Ikeda; K Tamai; J Kato; K Segawa; E Yoshida; S Nishimura; Y Taya
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

5.  Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.

Authors:  Tomomi Nakajima; Kyoko Kitagawa; Tatsuya Ohhata; Satoshi Sakai; Chiharu Uchida; Kiyoshi Shibata; Naoko Minegishi; Kanae Yumimoto; Keiichi I Nakayama; Kazuma Masumoto; Fuminori Katou; Hiroyuki Niida; Masatoshi Kitagawa
Journal:  J Biol Chem       Date:  2015-02-10       Impact factor: 5.157

6.  Cyclin-dependent kinase 5 is required for associative learning.

Authors:  André Fischer; Farahnaz Sananbenesi; Christina Schrick; Joachim Spiess; Jelena Radulovic
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

Review 7.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

8.  Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1).

Authors:  Min Wei; Bingya Liu; Qinlong Gu; Liping Su; Yingyan Yu; Zhenggang Zhu
Journal:  Cell Oncol (Dordr)       Date:  2012-11-27       Impact factor: 6.730

9.  The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification.

Authors:  Mary K Harrison; Arsene M Adon; Harold I Saavedra
Journal:  Cell Div       Date:  2011-01-27       Impact factor: 5.130

10.  Four butyrolactones and diverse bioactive secondary metabolites from terrestrial Aspergillus flavipes MM2: isolation and structure determination.

Authors:  Mohamed Ms Nagia; Mohammad Magdy El-Metwally; Mohamed Shaaban; Soheir M El-Zalabani; Atef G Hanna
Journal:  Org Med Chem Lett       Date:  2012-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.